Elevated Serum Alanine Transaminase (ALT) in Patients of Type 2 Diabetes Mellitus

Objective: The objective of this study was to determine the prevalence of raised serum alanine transaminase level in patients of type 2 diabetes mellitus. Design: cross-sectional study Study Settings: This study was conducted at Department of Internal Medicine Abbas Institute of Medical Sciences Muzaffarabad from November 2020 to April 2021. Material and Methods: Total 144 patients were included in the study having age from 18 to 60 of both genders with Type 2 DM. It was labeled as elevated if it was >= 50 IU/L. A written informed consent was taken from each patient. Results: Patient's age ranged from 36 to 70 years having mean value of 44.4 +/- 8.3 y. BMI ranged from 21.2 Kg/m(2) to 34.7 Kg/m(2) with a mean of 27.2 +/- 3.7 Kg/m(2). Disease duration was from 2 to 14 years with a mean of 7.1 +/- 3.8 years. Elevated serum ALT was noted in 38 (26.4%) patients with type-II diabetes. Conclusion: Elevated serum ALT was noted in a substantial proportion of patients with type-II diabetes and was significantly more frequent in patients with poor glycemic control which warrants good glycemic control to prevent and routine screening of such patients in future practice to timely identify and manage this complication to improve the outcome.